ArticleFrontiers in oncology2025
Exploring the clinical and histopathological characteristics on breast phyllodes tumors predictors and prognosis in a real world.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Study objective: Phyllodes tumors of the breast (PT) are rare fibroepithelial tumors with varied clinical and histopathological characteristics, and standardized with wide margins in surgery, a systemic retrospective study of PT could improve our understanding of prognosis. Design: We conducted a retrospective study spanning 2008-2021, which included 333 cases of PT for chart review. We used logistic regression and comparison tests to evaluate the association between clinical features and local recurrence (LR), as well as to summarize overall survival (OS) and disease-free survival (DFS). Setting: Phyllodes tumors of the breast exhibit a propensity for a higher recurrence rate. The surgical protocol advocates for achieving wide margins (>1 cm), which presents challenges in clinical practice due to the ambiguity in defining such margins. Participants: A retrospective screening identified 333 cases of PT for inclusion in the study. Comprehensive data for this analysis was extracted from the clinical patient records. Interventions: Post-operation, all cases were subjected to a standardized protocol of regular follow-up , with subsequent documentation of follow-up data. Main outcome measures: At a median follow-up of 79 (inter-quartile range: 28-109) months, recurrence occurred in 9.7% (19/196) of benign, 18.4% (18/98) of borderline, and 28.2% (11/39) of malignant tumors. Local recurrence was not reduced with enlarged margin width (<1 cm vs. >1 cm: odds ratio (OR)=0.84; 95% CI, 0.48 to 1.47; p=0.53), but it was associated with age (<40 vs. >40: OR=2.04; 95% CI, 1.13 to 3.68; p=0.01). LR was significantly correlated with mitosis (<5/HFP vs. >=5/HFP: OR=0.56; 95% CI, 0.32 to 0.98; p=0.003), stromal overgrowth (yes vs. no: OR=0.43; 95% CI, 0.32 to 0.98; p=0.014), and stromal atypia (mild vs. marked: OR=0.59; 95% CI, 0.30 to 1.17; p=0.003). Result and conclusion: This retrospective study confirmed that recurrence and prognosis were not associated with wide margins in the real world, as suggested by previous guidelines, possibly due to the influence of characteristics such as age, stromal overgrowth, stromal atypia, and mitosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.